These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19425222)

  • 1. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial.
    Calmy A; Gayet-Ageron A; Montecucco F; Nguyen A; Mach F; Burger F; Ubolyam S; Carr A; Ruxungtham K; Hirschel B; Ananworanich J;
    AIDS; 2009 May; 23(8):929-39. PubMed ID: 19425222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana.
    Mosepele M; Mohammed T; Mupfumi L; Moyo S; Bennett K; Lockman S; Hemphill LC; Triant VA
    Cardiovasc J Afr; 2018 May/Jun 23; 29(3):155-161. PubMed ID: 29771268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.
    Hattab S; Guiguet M; Carcelain G; Fourati S; Guihot A; Autran B; Caby F; Marcelin AG; Costagliola D; Katlama C
    HIV Med; 2015 Oct; 16(9):553-62. PubMed ID: 25944318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.
    Porter BO; Shen J; Kovacs JA; Davey RT; Rehm C; Lozier J; Csako G; Nghiem K; Costello R; Lane HC; Sereti I
    AIDS; 2009 Sep; 23(15):2015-9. PubMed ID: 19617815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial.
    McDonald B; Moyo S; Gabaitiri L; Gaseitsiwe S; Bussmann H; Koethe JR; Musonda R; Makhema J; Novitsky V; Marlink RG; Wester CW; Essex M
    AIDS Res Hum Retroviruses; 2013 Jul; 29(7):993-9. PubMed ID: 23590237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
    Martínez E; D'Albuquerque PM; Llibre JM; Gutierrez F; Podzamczer D; Antela A; Berenguer J; Domingo P; Moreno X; Perez I; Pich J; Gatell JM;
    AIDS; 2012 Nov; 26(18):2315-26. PubMed ID: 23018438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
    Kroon ED; Ungsedhapand C; Ruxrungtham K; Chuenyam M; Ubolyam S; Newell ME; van Leeuwen R; Kunanusont C; Buranapraditkul S; Sirivichayakul S; Lange JM; Cooper DA; Phanuphak P
    AIDS; 2000 Jul; 14(10):1349-56. PubMed ID: 10930149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genital shedding of HIV after scheduled treatment interruption.
    Ananworanich J; Kerr SJ; Vernazza P; Mangclaviraj S; Chaithongwongwatthana S; Chotnopparatpattara P; Mahanontharit A; Ubolyam S; Jupimai T; Cooper DA; Ruxrungtham K; Hirschel B;
    Int J STD AIDS; 2011 Feb; 22(2):61-6. PubMed ID: 21427425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Markers of endothelial injury and plasma adipocytokine in antiretroviral-naive HIV patients].
    Li L; Chen J; Sun FY; Liu L; Zhang RF; Zheng YF; Lu HZ
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):136-9. PubMed ID: 21418835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment.
    van den Ham HJ; Cooper JD; Tomasik J; Bahn S; Aerts JL; Osterhaus ADME; Gruters RA; Andeweg AC;
    PLoS One; 2018; 13(2):e0192278. PubMed ID: 29389978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
    Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL
    J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
    Fox Z; Dragsted UB; Gerstoft J; Phillips AN; Kjaer J; Mathiesen L; Youle M; Katlama C; Hill A; Bruun JN; Clumeck N; Dellamonica P; Lundgren JD;
    Antivir Ther; 2006; 11(6):761-70. PubMed ID: 17310820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
    Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
    J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study.
    De Luca A; de Gaetano Donati K; Colafigli M; Cozzi-Lepri A; De Curtis A; Gori A; Sighinolfi L; Giacometti A; Capobianchi MR; D'Avino A; Iacoviello L; Cauda R; D'Arminio Monforte A
    BMC Infect Dis; 2013 Sep; 13():414. PubMed ID: 24004495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study.
    Wada NI; Bream JH; Martínez-Maza O; Macatangay B; Galvin SR; Margolick JB; Jacobson LP
    Clin Infect Dis; 2016 Oct; 63(7):984-990. PubMed ID: 27343547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.